JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online January 16, 2008, 10.2967/jnumed.107.045526
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.045526v1
49/2/255    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.
Journal of Nuclear Medicine Vol. 49 No. 2 255-259
© 2008 by Society of Nuclear Medicine
doi: 10.2967/jnumed.107.045526

Brief Communication

Patterns of {alpha}vβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET

Ambros J. Beer1, Markus Niemeyer2, Janette Carlsen1, Mario Sarbia3, Jörg Nährig3, Petra Watzlowik1, Hans-Jürgen Wester1, Nadia Harbeck2 and Markus Schwaiger1

1 Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 2 Department of Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; and 3 Department of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Correspondence: For correspondence or reprints contact: Ambros J. Beer, MD, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: beer{at}roe.med.tum.de


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 
The integrin {alpha}vβ3 is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the {alpha}vβ3-selective PET tracer 18F-galacto-RGD in invasive ductal breast cancer. Methods: Sixteen patients with primary (n = 12) or metastasized breast cancer (n = 4) were examined with 18F-galacto-RGD PET. Standardized uptake values (SUVs) were derived by region-of-interest analysis, and immunohistochemistry of {alpha}vβ3 expression was performed (n = 5). Results: 18F-Galacto-RGD PET identified all invasive carcinomas, with SUVs from 1.4 to 8.7 (mean ± SD, 3.6 ± 1.8; tumor-to-blood and tumor-to-muscle ratios, 2.7 ± 1.6 and 6.2 ± 2.2, respectively). Lymph-node metastases were detected in 3 of 8 patients (mean SUV, 3.3 ± 0.8). SUVs in distant metastases were heterogeneous (2.9 ± 1.4). Immunohistochemistry confirmed {alpha}vβ3 expression predominantly on microvessels (5/5) and, to a lesser extent, on tumor cells (3/5). Conclusion: Our results suggest generally elevated and highly variable {alpha}vβ3 expression in human breast cancer lesions. Consequently, further imaging studies with 18F-galacto-RGD PET in breast cancer patients for assessment of angiogenesis or planning of {alpha}vβ3-targeted therapies are promising.

Key Words: breast cancer • integrins • {alpha}vβ3 • angiogenesis • PET • RGD


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 
The treatment of breast cancer nowadays requires an individualized approach and determination of the best therapeutic strategy. The integrin {alpha}vβ3 is an interesting target for specific therapies in oncology and as a new prognostic factor, as it is highly expressed on activated endothelial cells during angiogenesis and plays an important role in the regulation of tumor growth, local invasiveness, and metastatic potential (1–3). Specifically in breast cancer, its involvement in metastasis, and especially in migration of tumor cells to the bone, has been demonstrated in preclinical tumor models (4,5). Moreover, anti-{alpha}vβ3–targeted drugs, alone or in combination with radioimmunotherapy, have been proven to be effective in breast cancer xenografts (6,7). Histopathologic studies have examined the role of integrin {alpha}vβ3 in human breast cancer and have shown contradicting results (8–11). Molecular imaging has the potential to show specific biologic properties of tissues as a whole and also in several tumor sites in the body in one session (12). Therefore, imaging of {alpha}vβ3 expression might help to elucidate the complex role of this integrin in human breast cancer patients. We have developed the {alpha}vβ3-specific tracer 18F-galacto-RGD for PET (13). It has already been demonstrated that 18F-galacto-RGD PET allows specific imaging of {alpha}vβ3 expression and that the uptake of 18F-galacto-RGD correlates with {alpha}vβ3 expression in tumor xenografts as well as in patients (14–17). We now report—to our knowledge, for the first time—on the specific use of 18F-galacto-RGD PET in breast cancer patients. The goals of our study were to analyze the uptake patterns of 18F-galacto-RGD in normal breast tissue and in primary as well as metastatic tumor lesions. Our hypothesis was that 18F-galacto-RGD PET allows for identification of {alpha}vβ3 expression in primary and metastatic breast cancer lesions with good image quality, which, in consequence, would demonstrate its usefulness for future applications such as noninvasive assessment of angiogenesis and integrin {alpha}vβ3 expression in human breast cancer.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 CONCLUSION
 References
 
Radiopharmaceutical Preparation
Synthesis of the labeling precursor and subsequent 18F labeling were performed as described previously (18).

Patients
The study was approved by the Ethics Committee of the Technische Universität München, and informed written consent was obtained from all patients. Sixteen patients were included in the study (15 female, 1 male; mean age ± SD, 62.1 ± 11.7 y).

Inclusion criteria consisted of:

Exclusion criteria consisted of pregnancy, lactation period, and impaired renal function (serum creatinine level > 1.2 mg/dL).

For details on the patient population, see Table 1.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Patient Data

 
PET Procedure
Imaging was performed with an ECAT EXACT PET scanner (Siemens Medical Solutions, Inc.) as described previously (17). In each subject, a static emission scan was acquired in the caudocranial direction, beginning on average 63.0 ± 4.1 min (mean ± SD) after injection of 18F-galacto-RGD, covering a field of view at least from the pelvis to the thorax (5–7 bed positions, 5 min per bed position). The imaging time point was chosen according to former results from dynamic and serial static emission scans, showing good tumor-to-background contrast ~60 min after injection (14).

Image Analysis
Positron emission data were reconstructed using the ordered-subsets expectation maximization (OSEM) algorithm using 8 iterations and 4 subsets. The images were corrected for attenuation using the collected transmission data. For image analysis, CAPP software, version 7.1 (Siemens Medical Solutions, Inc.), was used. The static emission scans were calibrated to standardized uptake values (SUVs).

In the static emission scans, circular regions of interest (ROIs) with a diameter of 1.5 cm were placed over the left ventricle, the forearm (muscle tissue activity), breast tissue on the contralateral side to the tumor-bearing breast, liver, spleen, lung, and tumor tissue in 3 adjacent slices by an experienced operator. Polygonal free-hand ROIs were placed over the intestine in areas with visible tracer uptake in the lower abdomen. Results were expressed in mean SUV. In the tumors, the areas with the maximum intensity were chosen for measurements. In tumors with a diameter of ≤2 cm and visible uptake (n = 4), the SUV might be underestimated because of partial-volume effects. Therefore, the diameter of the ROI was adapted to the tumor size, and the SUV in the ROI was corrected for partial-volume effects using the tumor diameter mentioned in the pathology report and the correction tables established by Brix et al. for our PET scanner by phantom studies (19).

For evaluation of the sensitivity of 18F-galacto-RGD for primary staging, lesions with elevated uptake on 18F-galacto-RGD PET were compared with the results of conventional staging, and histopathologic staging served as the standard of reference. For evaluation of metastatic lesions, the findings of clinical staging served as the standard of reference. A maximum of 10 lesions was evaluated per patient, as 2 patients had disseminated metastatic disease to the liver and bone.

Collection of Tissue Samples and Immunohistochemistry of {alpha}vβ3 Expression
The mean time interval between PET and surgery was 2.4 ± 2.3 d. In the operating room, tissue samples from the tumors were obtained from tumor regions with maximum tracer uptake. The specimens were snap-frozen in liquid nitrogen and stored at –70°C until staining was performed.

For immunohistochemical investigation, frozen tumor tissues were sectioned (6 µm) and stained using the biotinylated monoclonal anti-{alpha}vβ3 antibody LM609 (1:100; Chemicon Europe). Sections were processed by peroxidase staining (peroxidase substrate AEC [3-amino-9-ethylcarbazole] kit; Vector Laboratories).

Analysis of staining of microvessel and tumor cells was performed by a senior pathologist, who was unaware of the results of the SUV measurements.

Statistical Analysis
All quantitative data are expressed as mean ± 1 SD. The correlation between quantitative parameters was evaluated by linear regression analysis and by calculation of the Pearson correlation coefficient R. Statistical significance was tested by using ANOVA. All statistical tests were performed at the 5% level of statistical significance, using MedCalc statistical software (version 6.15.000).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 CONCLUSION
 References
 
Static Emission Scans
During the observation period of ~3 h after tracer injection until the end of scanning, no adverse reactions were noted in our patient population.

The results of the SUV measurements are summarized in Figure 1. The mean tumor-to-blood ratio was 2.9 ± 1.7, and the mean tumor-to-muscle ratio was 6.6 ± 1.9. The SUVs of the primary tumors (n = 12) did not correlate with the tumor diameter (r = 0.116, P = 0.719).


Figure 1
View larger version (7K):
[in this window]
[in a new window]

  		FIGURE 1.  Box plot diagram of mean SUVs of tumors and normal tissue (breast, muscle, blood pool, liver, spleen, lungs, intestine) from static emission scans. Tumor uptake was very heterogeneous but higher than uptake in background tissue, resulting in good image contrast.

 
Comparison with Clinical Staging
In the static emissions scans, all primary tumors could be identified (n = 12/12). No false-positive findings occurred in the tumor-bearing or the contralateral breast. One patient was scanned after completion of neoadjuvant chemotherapy with no residual viable tumor cells in histology (ypT0) and no elevated signal on the 18F-galacto-RGD PET scan. One patient with a suggestive finding according to mammography and MRI mammography (BIRADS 4) showed no elevated uptake on the 18F-galacto-RGD PET scan, and no tumor was found on histopathology. Lymph-node metastases were detected in 3 of 8 patients with a mean SUV of 3.3 ± 0.8. Although the mean size of the missed metastases was small—5.8 ± 7.2 mm—not only microscopic but also macroscopic lymph-node metastases were missed (size, 15 and 20 mm). Eleven of 24 evaluated distant metastases were detected by 18F-galacto-RGD PET and SUVs were heterogeneous (mean, 2.9 ± 1.4; range, 1.0–3.8). Osseous metastases were depicted successfully by 18F-galacto-RGD PET on a per-patient basis (n = 4); however, some osseous metastases in the same patients did not show tracer uptake. Also, multiple metastases to the liver were not identified in 1 patient. One small lung lesion was detected by 18F-galacto-RGD PET, which was not detected by conventional staging, and which was confirmed by CT (Fig. 2).


Figure 2
View larger version (92K):
[in this window]
[in a new window]

  		FIGURE 2.  A 70-y-old patient with invasive ductal breast cancer of left breast (arrow, open tip), axillary lymph-node metastases on left side (arrow, open tip, dotted line), an osseous metastasis to the sternum (arrow, closed tip), and a pulmonary metastasis on right side (arrow, closed tip, dotted line). Maximum-intensity projection of 18F-galacto-RGD PET (A) and planar images (B, axial plane; C, coronal plane; D, axial plane) show primary tumor, lymph-node metastases, and osseous metastasis with good tumor-to-background contrast. High tracer retention is notable in urogenital tract, predominantly due to renal tracer elimination. Intermediate uptake is notable in liver, spleen, and intestine. One small pulmonary lesion was notable in nonattenuation–corrected images (E) and confirmed by CT (F). In the context of metastasized breast cancer, this was considered to be highly suggestive of a pulmonary metastasis.

 
Immunohistochemistry of {alpha}vβ3 Expression
{alpha}vβ3 expression could be confirmed by immunohistochemistry in all tumor specimens. {alpha}vβ3 expression was identified predominantly on the endothelium of newly formed blood vessels. In 3 specimens, {alpha}vβ3 expression could also be seen on the tumor cells themselves in addition to staining of the neovasculature (Fig. 3).


Figure 3
View larger version (87K):
[in this window]
[in a new window]

  		FIGURE 3.  Comparison of 18F-galacto-RGD PET (A and D) and immunohistochemistry of {alpha}vβ3 expression (B, C, E, and F). (Upper row) Patient with large invasive ductal carcinoma of left breast and low 18F-galacto-RGD uptake (A, arrow). Corresponding immunohistochemistry shows negative staining of most parts of tumor (C, low magnification) and only faint positive staining of single vessels (D, high magnification; arrow). (Lower row) Patient with invasive ductal carcinoma of left breast and intense 18F-galacto-RGD uptake (D, arrow). Corresponding immunohistochemistry (E, low magnification; F, high magnification) shows intense staining of tumor vessels (arrow).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
CONCLUSION
 References
 
In this study we could demonstrate elevated but highly variable {alpha}vβ3 expression in primary and metastatic breast cancer by using 18F-galacto-RGD and PET, with the integrin being expressed predominantly on endothelial cells and, to a lesser extent, on tumor cells. 18F-Galacto-RGD PET performed well for primary tumor detection but did not show sufficient sensitivity for lymph-node staging.

Our results demonstrated 18F-galacto-RGD uptake in all primary tumor lesions, which was very heterogeneous and did not depend on tumor size. Tracer uptake in metastases also was very heterogeneous. This suggests generally elevated but widely varying levels of {alpha}vβ3 expression in human breast cancer. This information contributes to the growing literature about integrin expression in human breast cancer, as results from former histopathologic studies were contradictory (8,11). Up to now, only 1 other study has examined {alpha}vβ3 expression in humans with imaging methods using the {alpha}vβ3-specific SPECT (single-photon CT) tracer 99mTc-NC100692 (20). Our results illustrate that noninvasive imaging of {alpha}vβ3 expression with PET is feasible with good quality in breast cancer patients. However, the small number of patients studied is a limitation, and further prospective studies using 18F-galacto-RGD in a larger patient population to evaluate the biologic and clinical significance of this tracer in more detail are warranted.

The immunohistochemistry of {alpha}vβ3 expression in primary tumors in our study revealed {alpha}vβ3 expression predominantly on endothelial cells as well as on tumor cells. Therefore, the signal from 18F-galacto-RGD PET represents a mixture of tracer binding on neovasculature and on tumor cells. This is in accordance with clinical as well as preclinical reports that describe {alpha}vβ3 expression on neovasculature and on breast cancer cells (8). Consequently, {alpha}vβ3 imaging for assessment of angiogenesis alone should be interpreted carefully in the context of breast cancer as part of the signal might be attributed to tumor cells and not to neovasculature alone. Quantification of {alpha}vβ3 expression in tumor specimens and correlation with tracer uptake was not performed because of the low number of samples, which is a limitation of our study. However, a significant correlation of {alpha}vβ3 expression in immunohistochemistry and 18F-galacto-RGD uptake has been demonstrated previously in murine tumor models as well as in patients using static emission scans such as in the current study (16,17).

18F-Galacto-RGD PET also showed good results relating to the identification of primary lesions with no false-positive results in breast cancer. However, it must be noted that only lesions with a diameter of 15 mm or larger were included in our study, because visualization of smaller lesions might be problematic due to the limited resolution of a clinical PET scanner, which is in the range of 5–6 mm (12). Moreover, primarily invasive ductal carcinomas were examined in our study, so no conclusions can be drawn about the efficacy of 18F-galacto-RGD PET for imaging of lobular carcinoma. The sensitivity for lymph-node metastases or distant metastases in our small patient sample was not adequate for use in N or M staging in clinical routine. This still must be evaluated in more detail in future comparative studies.


   CONCLUSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
References
 
Imaging of {alpha}vβ3 expression in invasive ductal breast cancer with 18F-galacto-RGD PET is possible with good image quality, with {alpha}vβ3 expression being elevated but highly variable in primary tumors as well as in metastases.


   ACKNOWLEDGMENTS
 
We thank the Cyclotron and PET team—especially Michael Herz, Gitti Dzewas, Coletta Kruschke, and Nicola Henke for excellent technical assistance—and the Münchner Medizinische Wochenschrift and the Sander Foundation for financial support.


   FOOTNOTES
 
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


   References
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 CONCLUSION
 References
 

  1. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.[CrossRef][Medline]
  2. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83–90.[CrossRef][Medline]
  3. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin {alpha}vβ3 for angiogenesis. Science. 1994;2674:569–571.
  4. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:9482–9487.[Abstract/Free Full Text]
  5. Liapis H, Flath A, Kitazawa S. Integrin alphavbeta3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5:127–135.[CrossRef][Medline]
  6. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alphavbeta3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815–1822.[Medline]
  7. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alphavbeta3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263–4272.[Abstract/Free Full Text]
  8. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alphavbeta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4:2625–2634.[Abstract]
  9. Damjanovich L, Fulop B, Adany R, Nemes Z. Integrin expression on normal and neoplastic human breast epithelium. Acta Chir Hung. 1997;36:69–71.[Medline]
  10. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol. 1992;23:1159–1166.[CrossRef][Medline]
  11. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004;30:484–489.[CrossRef][Medline]
  12. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282–3292.[Abstract/Free Full Text]
  13. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alphavbeta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785.[Abstract/Free Full Text]
  14. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the {alpha}vβ3 selective tracer 18F galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–1341.[Abstract/Free Full Text]
  15. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alphavbeta3 expression. J Nucl Med. 2006;47:763–769.[Abstract/Free Full Text]
  16. Haubner R, Weber WA, Beer AJ, et al. Non-invasive visualization of the activated {alpha}vβ3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med. March 29, 2005 [Epub ahead of print].
  17. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin alphavbeta3 expression in man. Clin Cancer Res. 2006;12:3942–3949.[Abstract/Free Full Text]
  18. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61–69.[CrossRef][Medline]
  19. Brix G, Bellemann ME, Hauser H, et al. Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination. Nuklearmedizin. 2002;41:184–190.[Medline]
  20. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434–1439.[Abstract/Free Full Text]
Received for publication July 20, 2007. Accepted for publication October 12, 2007.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
 JNMHome page
M. S. Morrison, S.-A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge
Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy
J. Nucl. Med., January 1, 2009; 50(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. R. Hsu and X. Chen
Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis
J. Nucl. Med., April 1, 2008; 49(4): 511 - 514.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.045526v1
49/2/255    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beer, A. J.
Right arrow Articles by Schwaiger, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE